KalVista Pharmaceuticals Appoints Daniel B. Soland to Board of Directors
Daniel Soland has been appointed to Kalvista Board of Directors .
Pharmaceuticals, Biotechnology and Life Sciences
Daniel Soland has been appointed to Kalvista Board of Directors .
Aura Biosciences’ lead productcandidate for the primary treatment of primary choroidal melanoma, willbe highlighted in a poster presentation at the Association for Researchin Vision and Ophthalmology (ARVO) 2019 Annual Meeting
BELRAPZO is indicated for the treatment of patients with indolent B-cellnon-Hodgkin lymphoma (NHL) that has progressed during or within sixmonths of treatment with rituximab or a rituximab-containing regimen.
many patients with advancedrenal cell carcinoma need additional treatment options that can helpimprove survival outcomes
BERWYN, Pa.–(BUSINESS WIRE)–In recognition of the Drug Enforcement Administration’s (DEA) National Prescription Drug Take Back Day, April 27, 2019, AscellaHealth…
In this pilot project, the Susmed system uses blockchain technology, which isexpected to be more cost-effective than conventional methods inmonitoring of clinical researches and ensuring data accuracy duringmonitoring.
The license allows the current FSD facility to supply and sell cannabisproducts. The company expects receiving the amended sales licensethat will include the sale of dried and fresh cannabis flower in thenear future.
The global anticoagulants reversal drugs market expected to expand at aCAGR of 15.3% from 2018 to 2026, owing to the approval of blockbusterdrugs in recent years and strong pipeline driving the market.
DUBLIN–(BUSINESS WIRE)–The “Anterior Uveitis – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering. The report offers comprehensive…
DUBLIN–(BUSINESS WIRE)–The “Global Chemotherapy Drugs Market: Analysis By Drug Type (Antimetabolites, Plant Alkaloids, Alkylating Agents, Antitumor Antibiotics), By Administration (Oral,…